Treating patients with lung cancer always calls for a focus on informed and shared decision-making, according to expert ...

Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted ...

In the DESTINY-Breast09 trial, presented at this year's American Society of Clinical Oncology (ASCO) annual meeting, first-line trastuzumab deruxtecan (T-DXd; Enhertu) combined with pertuzumab ...

Dr. Joshua K. Sabari and Dr. Prantesh Jain delve into key lung cancer outcomes from the 2025 ASCO Meeting that patients should be aware of.

Small-cell lung cancer (SCLC) is one of the most lethal cancers, with patients diagnosed with extensive-stage small-cell lung cancer (ES-SCLC) experiencing a median survival of just 12 months after ...

Also contributing are women’s higher rates of thyroid cancer, and rising rates of cervix and uterus cancers. And while lung cancer rates are decreasing for everyone, they’re declining more ...

Scientists have discovered tumors can tap a nontraditional pathway to acquire lipoproteins—molecules that transport fat in ...

The timing of immunotherapy initiation is not a significant factor in the outcomes of patients with extensive-stage small ...

Lung cancer is one of the most frequently diagnosed cancers and the leading cause of cancer-related deaths worldwide with an estimated 2 million new cases and 1·76 million deaths per year. Substantial ...